Project 1: Remodeling Chromatin and the Tumor Microenvironment: Direct Oncogenesis and Therapeutic Targeting
项目 1:重塑染色质和肿瘤微环境:直接肿瘤发生和治疗靶向
基本信息
- 批准号:10443720
- 负责人:
- 金额:$ 33.26万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-03-12 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:ATAC-seqAllelesBRAF geneBehaviorBioinformaticsBiological MarkersBiopsyBiopsy SpecimenCancer cell lineCatalytic DomainCell LineCell SurvivalCellsChIP-seqChromatinChromatin Remodeling FactorClinicalCollaborationsCytotoxic T-LymphocytesDNA PackagingData SetDependenceDevelopmentDimerizationEZH2 geneEngineeringEnzymesEpigenetic ProcessExhibitsGene Expression RegulationGenesGeneticGenetic TranscriptionGenomicsGoalsGrowthHistonesHumanImmuneImmune EvasionImmunologicsImmunosuppressionImmunotherapyIn VitroLysineMEK inhibitionMEKsMalignant NeoplasmsMeasurementMeasuresMediator of activation proteinMelanoma CellMessenger RNAMethylationMethyltransferaseModelingMusMutationOncogenesOncogenicPathway interactionsPatientsPharmacologyPoint MutationPre-Clinical ModelRecurrenceResistanceRoleSET DomainShapesSignal TransductionSpecimenT-LymphocyteTestingThe Cancer Genome AtlasTherapeuticTitrationsTranslationsTreatment EfficacyWNT Signaling PathwayXenograft procedureZebrafishantagonistanti-PD-1beta catenincell motilitycheckpoint therapychromatin remodelingcombinatorialdraining lymph nodedrug candidategenome-wideimprovedin vivoinhibitorinterestknock-downloss of functionloss of function mutationmelanomamouse modelmutantneoantigensneoplastic cellnovelnovel markeroverexpressionrefractory cancerresponsescreeningsmall hairpin RNAsmall molecule inhibitorsynergismtargeted treatmenttherapeutic targettranscriptome sequencingtreatment responsetumortumor microenvironmenttumor-immune system interactionstumorigenesistumorigenic
项目摘要
PROJECT SUMMARY
A synthetic lethality screen was performed to identify hyper-dependencies in melanomas harboring
deficiencies in ARID genes—components of the SWI/SNF chromatin remodelers—which occur in 20-30% of
human cancers. ARID mutant melanomas exhibited extreme dependency on the H3K9-dimethylase G9a, a
druggable enzyme. This led to discovery of 6 melanoma cases harboring recurrent point mutation at an
identical residue in G9a’s catalytic domain. The mutation hyper-activates G9a and aligns to oncogenic
mutations in EZH2, a previously known oncogenic methyltransferase that targets a different histone-3 lysine
(K27). Beyond these rare activating G9a mutations we identified more common genomic G9a copy gains in
27.8% of melanomas in TCGA and found G9a dependency (via genetic or pharmacologic means) in human
melanoma lines with as little as one extra G9a copy. Corroborating our results, the Achilles Project (genome-
scale loss-of-function viability screening in many deeply annotated cancer cell lines) confirmed G9a
dependency among melanoma lines harboring either G9a amplification or ARID deficiency. The same
dependencies were also seen in multiple cancers beyond melanoma in Achilles. Furthermore, G9a copy gain
was accompanied by global elevations in H3K9 dimethylation, which correlated as a biomarker of G9a
dependency in G9a gained/amplified melanoma cells. Mechanistic studies revealed activation of the canonical
Wnt pathway as a vital dependency target, which is induced by G9a’s suppression of Wnt antagonist DKK1.
Tumor intrinsic Wnt activation is common in melanomas, though usually without pathway-intrinsic mutations—a
phenomenon now largely explained by G9a activation. Importantly, Wnt activity has been strongly implicated
by others as a trigger of tumor-induced immune evasion—of keen interest for efficacy of immunotherapy. Here,
Aim 1 will validate dependencies of G9a copy-gained and ARID loss-of-function human melanoma lines on
G9a, GLP, MITF, DKK1, and Wnt signaling. Global ATAC-seq, RNA-seq, and H3K9me2-ChIP-seq will be used
to identify additional G9a targets and mediators of viability in these melanomas. Aim 2 will test pharmacologic
G9a inhibition in multiple mouse and zebrafish models containing copy gains of G9a or GLP, or ARID2
deficiency, combined with either BRAF-targeted therapy or anti-PD1 immunotherapy. The latter study will
utilize novel isogenic engineered syngeneic murine melanomas containing or lacking UV-neoantigens,
permitting measurements of G9a targeting as a strategy to blunt the Wnt pathway’s immunosuppressive
activity, together with direct targeting of G9a’s cell-intrinsic oncogenic function. Human melanoma biopsies will
also be interrogated to corroborate preclinical models. These studies identify a novel oncogene (G9a) and,
through vital collaborations with Dr. Zon (zebrafish melanoma model), Drs. Liu and Zon (epigenetic
mechanisms), and Drs. Wucherpfennig and Rodig (immunological profiling), will reveal mechanisms, novel
biomarkers, and therapeutic opportunities in melanoma, with relevance to other treatment-resistant cancers.
项目摘要
进行了一项综合致死性筛选,以确定黑色素瘤中的高度依赖性,
ARID基因缺陷-SWI/SNF染色质重塑的组成部分-发生在20-30%的
人类癌症ARID突变型黑色素瘤表现出对H3 K9-二甲基酶G9 a的极端依赖性,
药物酶这导致发现了6例黑色素瘤病例,
G9 a催化结构域中相同残基。该突变过度激活G9 a并与致癌基因
EZH 2中的突变,EZH 2是一种先前已知的致癌甲基转移酶,靶向不同的组蛋白-3赖氨酸
(K27)。除了这些罕见的激活G9 a突变,我们还发现了更多常见的基因组G9 a拷贝增加。
27.8%的黑色素瘤在TCGA中发现G9 a依赖性(通过遗传或药理学手段)
只有一个额外的G9 a拷贝的黑色素瘤细胞。为了证实我们的结果,阿基里斯项目(基因组-
在许多深度注释的癌细胞系中进行的大规模功能丧失活力筛选)证实了G9 a
具有G9 a扩增或ARID缺陷的黑素瘤细胞系之间的依赖性。相同的
依赖性也见于除跟腱黑色素瘤以外的多种癌症中。此外,G9 a拷贝增益
伴随着H3 K9二甲基化的全球升高,这与G9 a的生物标志物相关
G9 a依赖性获得/扩增的黑素瘤细胞。机制研究揭示了典型的激活
Wnt通路作为重要的依赖性靶点,其由G9 a抑制Wnt拮抗剂DKK 1诱导。
肿瘤内源性Wnt激活在黑色素瘤中很常见,尽管通常没有途径内源性突变,
这一现象现在主要由G9 a激活来解释。重要的是,Wnt活性与
被其他人认为是肿瘤诱导的免疫逃避的触发因素,这对免疫治疗的功效非常感兴趣。在这里,
目的1将验证G9 a拷贝获得和ARID功能丧失的人黑色素瘤细胞系对以下的依赖性:
G9 a、GLP、MITF、DKK 1和Wnt信号传导。将使用全局ATAC-seq、RNA-seq和H3 K9 me 2-ChIP-seq
以确定这些黑色素瘤中的其他G9 a靶点和存活介质。目标2将测试药理学
在含有G9 a或GLP或ARID 2拷贝增益的多种小鼠和斑马鱼模型中的G9 a抑制
缺乏,与BRAF靶向治疗或抗PD 1免疫治疗相结合。后一项研究将
利用含有或缺乏UV-新抗原的新的同基因工程化的同基因鼠黑素瘤,
允许测量G9 a靶向作为钝化Wnt途径免疫抑制的策略,
活性,以及直接靶向G9 a的细胞内在致癌功能。人类黑色素瘤活组织检查
也被询问以证实临床前模型。这些研究鉴定了一种新的癌基因(G9 a),
通过与Zon博士(斑马鱼黑色素瘤模型)、Liu博士和Zon博士(表观遗传学)的重要合作,
机制),Wucherpfennig和Rodig博士(免疫学分析),将揭示机制,新的
生物标志物和黑色素瘤的治疗机会,与其他耐药癌症相关。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID E FISHER其他文献
DAVID E FISHER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID E FISHER', 18)}}的其他基金
MITF from control of pigmentation to melanoma risk
MITF 从控制色素沉着到黑色素瘤风险
- 批准号:
10828041 - 财政年份:2023
- 资助金额:
$ 33.26万 - 项目类别:
A druggable dependency in low-MITF/high-AXL melanoma: preclinical efficacy and mechanism of action in a key treatment-resistant subclass.
低 MITF/高 AXL 黑色素瘤的药物依赖性:关键耐药亚类的临床前疗效和作用机制。
- 批准号:
10331800 - 财政年份:2018
- 资助金额:
$ 33.26万 - 项目类别:
Preclinical models and therapeutic strategies for treatment of giant congenital melanocytic nevi
先天性巨大黑素细胞痣的临床前模型及治疗策略
- 批准号:
9753925 - 财政年份:2017
- 资助金额:
$ 33.26万 - 项目类别:
Preclinical models and therapeutic strategies for treatment of giant congenital melanocytic nevi
先天性巨大黑素细胞痣的临床前模型及治疗策略
- 批准号:
9376481 - 财政年份:2017
- 资助金额:
$ 33.26万 - 项目类别:
Preclinical models and therapeutic strategies for treatment of giant congenital melanocytic nevi
先天性巨大黑素细胞痣的临床前模型及治疗策略
- 批准号:
10245261 - 财政年份:2017
- 资助金额:
$ 33.26万 - 项目类别:
Therapeutic strategies for treatment of giant congenital melanocytic nevi
巨大先天性黑素细胞痣的治疗策略
- 批准号:
10570507 - 财政年份:2017
- 资助金额:
$ 33.26万 - 项目类别:
Preclinical models and therapeutic strategies for treatment of giant congenital melanocytic nevi
先天性巨大黑素细胞痣的临床前模型及治疗策略
- 批准号:
9977915 - 财政年份:2017
- 资助金额:
$ 33.26万 - 项目类别:
Development of next-generation cancer functional diagnostics
下一代癌症功能诊断的开发
- 批准号:
8492572 - 财政年份:2013
- 资助金额:
$ 33.26万 - 项目类别:
Targetable epigenetic and transcriptional mechanisms in melanoma that shape the microenvironment
黑色素瘤中塑造微环境的靶向表观遗传和转录机制
- 批准号:
9792731 - 财政年份:2013
- 资助金额:
$ 33.26万 - 项目类别:
相似海外基金
Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
- 批准号:
502556 - 财政年份:2024
- 资助金额:
$ 33.26万 - 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
- 批准号:
10659303 - 财政年份:2023
- 资助金额:
$ 33.26万 - 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
- 批准号:
10674405 - 财政年份:2023
- 资助金额:
$ 33.26万 - 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
- 批准号:
10758772 - 财政年份:2023
- 资助金额:
$ 33.26万 - 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
- 批准号:
10676499 - 财政年份:2023
- 资助金额:
$ 33.26万 - 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
- 批准号:
2748611 - 财政年份:2022
- 资助金额:
$ 33.26万 - 项目类别:
Studentship
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
- 批准号:
10532032 - 财政年份:2022
- 资助金额:
$ 33.26万 - 项目类别:
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
- 批准号:
22K05630 - 财政年份:2022
- 资助金额:
$ 33.26万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
- 批准号:
10525070 - 财政年份:2022
- 资助金额:
$ 33.26万 - 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
- 批准号:
10689017 - 财政年份:2022
- 资助金额:
$ 33.26万 - 项目类别: